Relatient vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Patient scheduling and engagement platform for multi-specialty practices, combining intelligent scheduling, reminders, and digital intake. Franklin TN, raised $41M+.
About
Relatient is a patient engagement and scheduling company that provides healthcare providers with an integrated platform for scheduling automation, appointment reminders, digital check-in, and patient communication. Founded in 2013 and headquartered in Franklin, Tennessee, Relatient has raised more than $41 million and serves health systems, hospital outpatient departments, and multi-specialty physician groups across the United States. The company's Dash platform delivers intelligent self-scheduling, automated reminder workflows, digital intake forms, and post-visit survey capabilities through a single system that integrates with major EHR and practice management software.\n\nRelatiently's Dash scheduling platform is built around intelligent appointment matching, directing patients to the right provider, location, and appointment type based on clinical criteria and insurance requirements rather than offering a simple open calendar view. This smart scheduling approach reduces scheduling errors and the downstream revenue cycle problems they cause, while improving the patient experience by eliminating the friction of calling and navigating phone trees. The platform supports scheduling across complex multi-provider, multi-location organizations where routing rules are an important operational requirement.\n\nRelatiently competes in a market that has grown significantly as providers recognize the revenue and operational impact of patient access optimization. The company differentiates through its depth of EHR integration, its focus on enterprise multi-specialty environments, and its comprehensive approach to the full patient engagement lifecycle from first contact through post-visit follow-up. Relatient's combination of scheduling intelligence and communication automation serves as an integrated patient access solution for organizations that need more than basic reminder tools.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.